Next-generation antigen-presenting cell immune therapeutics for gliomas
Journal of Clinical Investigation · 01.02.2023 · 133 (3)
DOI: 10.1172/jci163449 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.02.2023. Verfasst von Catalina Lee-Chang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Glioma, Cancer Vaccines. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Antigen presentation machinery and professional antigen-presenting cells (APCs) are fundamental for an efficacious immune response against cancers, especially in the context of T cell-centric immunotherapy. Dendritic cells (DCs), the gold standard APCs, play a crucial role in initiating and maintaining a productive antigen-specific adaptive immunity. In recent decades, ex vivo-differentiated DCs from circulating CD14+ monocytes have become the reference for APC-based immunotherapy. DCs loaded with tumor-associated antigens, synthetic peptides, or RNA activate T cells with antitumor properties. This strategy has paved the way for the development of alternative antigen-presenting vaccination strategies, such as monocytes, B cells, and artificial APCs, that have shown effective therapeutic outcomes in preclinical cancer models. The search for alternative APC platforms was initiated by the overall limited clinical impact of DC vaccines, especially in indications such as gliomas, a primary brain tumor known for resistance to any immune intervention. In this Review, we navigate the APC immune therapeutics' past, present, and future in the context of primary brain tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Malnati Brain Tumor Institute, Chicago, Illinois, USA.
Förderung
- NCI NIH HHS
- NINDS NIH HHS
Zitieren
APA
Lee-Chang, C., & Lesniak, M. S. (2023). Next-generation antigen-presenting cell immune therapeutics for gliomas. Journal of Clinical Investigation, 133(3). https://doi.org/10.1172/jci163449
Vancouver
Lee-Chang C, Lesniak MS. Next-generation antigen-presenting cell immune therapeutics for gliomas. Journal of Clinical Investigation. 2023;133(3). doi:10.1172/jci163449
BibTeX
@article{LeeChang2023,
author = {Lee-Chang, Catalina and Lesniak, Maciej S},
title = {Next-generation antigen-presenting cell immune therapeutics for gliomas},
journal = {Journal of Clinical Investigation},
year = {2023},
volume = {133},
number = {3},
doi = {10.1172/jci163449}
}
EUVIMED